174 related articles for article (PubMed ID: 36225103)
1. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
Mendes D; Averin A; Atwood M; Sato R; Vyse A; Campling J; Weycker D; Slack M; Ellsbury G; Mugwagwa T
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1285-1295. PubMed ID: 36225103
[TBL] [Abstract][Full Text] [Related]
2. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
4. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
[TBL] [Abstract][Full Text] [Related]
5. Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.
Mugwagwa T; Averin A; Atwood M; Sato R; Vyse A; Campling J; Weycker D; Slack M; Ellsbury G; Mendes D
Expert Rev Vaccines; 2022 Sep; 21(9):1331-1341. PubMed ID: 35929956
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23.
Olsen J; Schnack H; Skovdal M; Vietri J; Mikkelsen MB; Poulsen PB
J Med Econ; 2022; 25(1):1240-1254. PubMed ID: 36426797
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
Kang DW; Kim CR; Song JY; Park SK
Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany.
Kühne F; Achtert K; Püschner F; Urbanski-Rini D; Schiller J; Mahar E; Friedrich J; Atwood M; Sprenger R; Vietri J; von Eiff C; Theilacker C
Expert Rev Vaccines; 2023; 22(1):921-932. PubMed ID: 37881844
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
[TBL] [Abstract][Full Text] [Related]
11. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
[TBL] [Abstract][Full Text] [Related]
12. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
Cantarero D; Ocaña D; Onieva-García MÁ; Rodríguez-García J; Gálvez P; Méndez C; Crespo C; López-Ibáñez de Aldecoa A
Vaccine; 2023 Aug; 41(36):5342-5349. PubMed ID: 37479615
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting.
Malene B M; Oyvind H; Tor M; David N M; Jens O; Nanna V K; Jeffrey V
Cost Eff Resour Alloc; 2023 Aug; 21(1):52. PubMed ID: 37559118
[TBL] [Abstract][Full Text] [Related]
16. Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai.
Zayed M; Joury J; Farghaly M; Al Dallal S; Mahboub B; Kutrieb E; Averin A
Curr Ther Res Clin Exp; 2023; 98():100698. PubMed ID: 37096181
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.
Nakamura S; Mikami M; Hayamizu T; Yonemoto N; Moyon C; Gouldson M; Crossan C; Vietri J; Kamei K
Expert Rev Vaccines; 2024; 23(1):546-560. PubMed ID: 38703180
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
